Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 7:47 PM
Ignite Modification Date:
2025-12-24 @ 7:47 PM
NCT ID:
NCT00901303
Eligibility Criteria:
Inclusion Criteria:
* Histologically documented classical Hodgkin lymphoma according to the WHO Classification. Nodular lymphocyte predominant Hodgkin lymphoma is excluded
* No prior treatment (chemotherapy or radiation therapy) for Hodgkin lymphoma
* Measurable disease must be present either on physical examination or imaging studies. Any tumor mass measurable in two dimensions and \> 2 cm is acceptable (or 1.5 cm if 0.5 cm slices are used as in spiral CT scans)
* Age ≥ 18
* Patients must have at least one hypermetabolic lesion identifiable on initial PET scan
* LVEF by ECHO or MUGA within institutional normal limits
* Initial laboratory data should be compatible with the administration of standard doses of ABVD chemotherapy
Exclusion Criteria:
* Patient has no known HIV infection
* Patient is non-pregnant and non-lactating. Due to the teratogenic potential of the agents used in this study, pregnant or nursing women may not be enrolled. Women and men of reproductive potential should agree to use an effective means of birth control
* No other history of lymphoproliferative disorder or granulomatous disease
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00901303
Study Brief:
Protocol Section:
NCT00901303